Pure Global
NCT06314217

Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME

Everads Injector in Suprachoroidal Administration of a Triamcinolone Acetonide (TA) Suspension Approved for Intraocular Injection, for the Treatment of Patients With Diabetic Macular Edema: An Open-label Safety and Performance Pilot Study
Everads Therapy·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetic Macular Edema
Drug/Device/Intervention
Everads Injector
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Everads Therapy
Location
Haifa, Israel
Timeline & enrollment
Phase
N/A
Start date
Feb 18, 2024
End date
Mar 30, 2025
Enrollment
10 participants
Primary outcome

Frequency of treatment-emergent adverse events,Frequency of adverse device effects

Summary

This is an open-label pilot device study. The aim of the study is to evaluate the safety and
 performance of Everads Injector following single injection of suspension approved for ocular
 use into the suprachoroidal space.
 
 The study population is patients diagnosed with diabetic macular edema (DME) that were
 previously treated. 10 adult subjects are expected to be enrolled based on the
 inclusion-exclusion criteria.
 
 The study will involve 6 visits during a period of 6 weeks

ICD-10 classifications
Diabetic retinopathyOther specified diabetes mellitus with ophthalmic complicationsUnspecified diabetes mellitus with ophthalmic complicationsDiabetic cataractType 2 diabetes mellitus with ophthalmic complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06314217
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06314217 through Pure Global AI's free database. This phase not specified trial is sponsored by Everads Therapy and is currently Recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.